2017
DOI: 10.1016/j.ijbiomac.2017.07.137
|View full text |Cite
|
Sign up to set email alerts
|

Development of alginate gel beads with a potential use in the treatment against acute lead poisoning

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
4
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(5 citation statements)
references
References 28 publications
1
4
0
Order By: Relevance
“…From the results shown in Figure S12 , we come to know that with the increase of n (LA): n (IDA), the Pb 2+ chelating capacity of P(LA- co -IDA)s is gradually decreased from 1.80 mg·g −1 of IDA8 to 0.33 mg·g −1 of IDA128. The datum is similar to ( Tahtat et al., 2017 ; El-Ashgar et al., 2017 ) or higher than ( Liu et al., 2020 ; Blicharska et al., 2018 ) that of the reported polymeric (or M w over 1,200 Da) Pb 2+ chelators using IDA or other substances as functional groups. Importantly, this level of chelating capacity is suitable for a potential biomedical chelating agent as a treatment drug for chelating and removing lead ions in vivo because the threshold of lead poisoning that requires treatment is 10 μg·dL −1 ( Balasubramanian et al., 2020 ), and the corresponding dosage of small molecule chelating drugs is as low as 30 mg·kg −1 body weight per day ( Safi et al., 2019 ).…”
Section: Resultssupporting
confidence: 81%
See 1 more Smart Citation
“…From the results shown in Figure S12 , we come to know that with the increase of n (LA): n (IDA), the Pb 2+ chelating capacity of P(LA- co -IDA)s is gradually decreased from 1.80 mg·g −1 of IDA8 to 0.33 mg·g −1 of IDA128. The datum is similar to ( Tahtat et al., 2017 ; El-Ashgar et al., 2017 ) or higher than ( Liu et al., 2020 ; Blicharska et al., 2018 ) that of the reported polymeric (or M w over 1,200 Da) Pb 2+ chelators using IDA or other substances as functional groups. Importantly, this level of chelating capacity is suitable for a potential biomedical chelating agent as a treatment drug for chelating and removing lead ions in vivo because the threshold of lead poisoning that requires treatment is 10 μg·dL −1 ( Balasubramanian et al., 2020 ), and the corresponding dosage of small molecule chelating drugs is as low as 30 mg·kg −1 body weight per day ( Safi et al., 2019 ).…”
Section: Resultssupporting
confidence: 81%
“…However, the traditional small molecule-type chelating agents have obvious disadvantages, such as large dosage, high toxicity, and non-biodegradation ( Bretti et al., 2017 ; He et al., 2019a , 2019b ). Thus, it is of great practical significance to develop polymeric chelators with biocompatibility, biodegradability, and long-term efficacy ( Tahtat et al., 2017 ; Bretti et al., 2019 ). As far as we know, to date, there have been no reports on such chelating agents based on PLA materials.…”
Section: Introductionmentioning
confidence: 99%
“…In hydrated acidic alginate gels the intermolecular hydrogen-bonding interactions are supposed to be partly weakened. , Consequently, fluid uptake into the ALG matrix is allowed, , and moderate swelling of the ALG beads occurs. The swelling capacity of ALG beads in SGF thus primarily depends on the ionic strength of H + , allowing replacement of the metal ions and the formation of acidic ALG gels.…”
Section: Resultsmentioning
confidence: 99%
“…For patients suffering from a lead poisoning crisis and having an urgent requirement for in vivo lead removal, these highly efficient adsorbents unavoidably cause the reaction of hemolysis, immune rejection, and secondary poisoning. [ 27 ] That means conventional adsorbents for environmental purification meet an obstacle to lead removal in the human body. Hence, new adsorbents with bio‐safe features are in urgent need.…”
Section: Introductionmentioning
confidence: 99%